Atara, reeling from FDA hold on Ebvallo, lays off half of workforce
Atara Biotherapeutics is halving its headcount as it navigates the fallout from the FDA’s move to halt on all of the allogeneic T-cell company’s attempts to launch fresh clinical trials.
Atara Biotherapeutics is halving its headcount as it navigates the fallout from the FDA’s move to halt on all of the allogeneic T-cell company’s attempts to launch fresh clinical trials.
